Lessons Learned from Managing Antithrombotic Therapy in Children Supported with Pediatric Ventricular Assist Devices. Issue 11 (2nd August 2022)

• Record Type: Journal Article
• Authors: Murray, Jenna M.; Miera, Oliver; Stiller, Brigitte; Maeda, Katsuhide; Almond, Christopher S.
• Is Part Of: ASAIO journal. Volume 68:Issue 11(2022)
• Page Start: 1321
• Page End: 1331
• Publication Date: 2022-08-02
• Subjects: anticoagulation -- Berlin Heart EXCOR VAD -- pediatrics -- stroke -- ventricular assist devices; Artificial organs -- Periodicals; 617
• DOI: 10.1097/MAT.0000000000001782
• Languages: English
• ISSNs: 1058-2916

Abstract

Abstract : Stroke, thromboembolism, and bleeding are the most recognized complications associated with pediatric ventricular assist devices (VADs) and the leading cause of death and disability on VAD support. Recently, newer antithrombotic strategies like bivalirudin have emerged that appear to be associated with a reduction in the neurologic event rates, especially for smaller pediatric-specific VADs like the Berlin Heart and PediMag/CentriMag systems where the risk of stroke is the highest. While contemporary antithrombotic therapies have likely contributed to lowering adverse event rates, we speculate that clotting and bleeding adverse events may have dropped because of a variety of other seemingly small changes to antithrombotic management that are independent of the antithrombotic agents used. This view is supported by recent reports documenting low stroke rates with anticoagulants other than bivalirudin, a drug that may have a wider therapeutic window but is not available in all locations throughout the world. The primary purpose of this report is 1) to summarize contemporary antithrombotic regimens used for smaller pediatric VADs today associated with low event rates in the United States and abroad and () to review 10 practical lessons learned and pitfalls to avoid that we believe to be important to reducing bleeding and clotting events based on our collective experience managing pediatric VADs over the past 20 years irrespective of the antithrombotic agents used.